VEGFA and neoplasm: Consequently, a variable part of the antiangiogenic activity of EGFR-targeting drugs could be caused by a dual effect: inhibition of proangiogenic factors such as VEGF produced by the tumour itself and a direct effect on the intra-tumour endothelial cells.